Primer Capital et al. in €1.7m round for Acticor Biotech

Primer Capital investment partner Timur Avdeenko has been appointed as an observer on the Acticor Biotech board.

Previous backers Anaxago and CapDecisif Management, as well as private investors, also committed to the round. 

The investment follows the recent grant of €2.2m received by Acticor from the Concours Mondial de l'Innovation. The funding will allow Acticor to prepare for its first clinical phase-II trial for its lead candidate.

Company
Acticor Biotech is a biopharmaceutical company founded in 2013 as a spin-off from Inserm. The clinical-stage biotechnology company is involved in the acute phase of thrombotic diseases, including stroke and other thrombosis disorders like pulmonary embolism. Acticor is headquartered in Paris.

People
Primer Capital – Elizaveta Rozhdestvenskaya (COO).
Acticor Biotech – Gilles Avenard (president).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• France
• Healthcare
• France
• Venture